ReportGem ReportGem 中文

GLOBAL RESEARCH ARCHIVE

Kone (AO) | Buy | Clear beat on order intake, in-line adjusted EBIT margin in Q2, 2026 outlook unchanged

Published: 2026-07-22Institution: Kepler CheuvreuxCompany / ticker: KNEBV.HEPages: 13Original language: 英语Evidence page: 3

Research evidence excerpt

Kone (AO) | Buy | Clear beat on order intake, in-line adjusted EBIT margin in Q2, 2026 outlook unchanged

Kone Buy | Target Price: EUR68.00

Company description Management

Post-merger Kone/TKE would be the global elevator and escalator leader, with Philippe Delorme (CEO)

c.22% value share after likely remedies. The group combines Kone’s Asian scale, Ilkka Hara (CFO)

digital capabilities and innovation base with TKE’s service-heavy franchise, Antti Herlin (Chairman)

installed base and Americas platform. It would offer a more balanced, Key shareholders

aftermarket-led profile, with stronger route density, modernisation reach, R&D Free float 62.67%

scale and targeted EUR700m annual cost synergies. The closing of the deal is Herlin Antti 23.35%

slated for Q2 2027 at the earliest. Polttina Oy 3.26%

Investment case Valuation methodology

The remaining hurdle for the Kone/TKE merger is antitrust, We employ a dual valuation approach, using the weighted

where we expect Germany-led European field remedies rather average fair value derived from a target multiple and our DCF

than deal prohibition. Our base case assumes Kone still retains model.

c. 85% of TKE sales and c. 80% of TKE adjusted EBITDA. We use an EV/EBITDA 2030E target multiple of 17x and discount

The industrial logic is strong and margin-relevant. Kone/TKE is a back the resulting fair value back to 12 months from now.

service-density, geographic-rebalancing and platform-efficiency Moreover, we use a three-stage DCF model with a ten-year time

deal. Even after remedies, the combined group would become horizon (WACC: 8.0%, TG: 2.25%).

the global E&E leader with c. 22% value share. Risks to our rating

The deal targets c. EUR700m cost synergies plus c. EUR200m Antitrust/remedy risk is the key downside case.

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer